LEG Immobilien SE

  • WKN: LEG111
  • ISIN: DE000LEG1110
  • Land: Deutschland

Nachricht vom 11.10.2021 | 04:48

LEG Immobilien SE: Conclusion of a letter of intent on the acquisition of properties of Adler Group

LEG Immobilien SE / Key word(s): Letter of Intent/Acquisition
LEG Immobilien SE: Conclusion of a letter of intent on the acquisition of properties of Adler Group

11-Oct-2021 / 04:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Düsseldorf, October 11, 2021

LEG Immobilien SE: Conclusion of a letter of intent on the acquisition of properties of Adler Group

- LEG Immobilien and Adler Group conclude letter of intent on the acquisition of approximately 15,350 residential units of the Adler Group by LEG Immobilien

- Subject to due diligence, LEG Immobilien will acquire the residential units at the current market price

- Parties agree on a period of exclusivity


LEG Immobilien SE and Adler Group S.A. have today, with the approval of their respective boards, entered into a letter of intent for the acquisition of approximately 15,350 residential units of Adler Group.

Subject to a standard market due diligence review, the parties have agreed that LEG Immobilien will acquire these residential properties at market price. Apart from that, the parties will finalize the further parameters of the agreement in the course of the next weeks. The parties have agreed on exclusivity for the purpose of due diligence and finalization of the relevant contractual documentation. The management of LEG Immobilien waives the contractually agreed transaction bonus for this transaction.

For LEG Immobilien, the arrangement with Adler Group is a consistent step in the expansion of its portfolio as part of its strategy. The portfolio is focused on LEG's core product ,affordable living'. The potential transaction would allow the company to further expand its market presence in North and Northwestern Germany - about 90 % of the units are located in Lower Saxony, Schleswig-Holstein and Bremen.


Contact:
Frank Kopfinger
Head of Investor Relations & Strategy

Tel. +49 (0)211/4568-550
Mob. +49 (0)1721739339
 

Information and Explanation of the Issuer to this News:

Important notice

This announcement is for information purposes only and neither constitutes an invitation to sell nor an offer to purchase securities.

To the extent any announcements in this document contain forward-looking statements, such statements do not represent facts and are characterized by the words 'will', 'expect', 'believe', 'estimate', 'intend', 'aim', 'assume' or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of LEG Immobilien and the persons acting jointly with LEG Immobilien. Such forward-looking statements are based on current plans, estimates and forecasts, which LEG Immobilien and the persons acting jointly with LEG Immobilien have made to the best of their knowledge, but which they do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by LEG Immobilien or the persons acting jointly with LEG Immobilien. These expectations and forward-looking statements can turn out to be incorrect and the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.


11-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021